Category: Biotech
-
Cybin (CYBN.NE) establishes Clinical Advisory Board as they gear up for trials
Cybin (CYBN.NE) announced they are forming a Clinical Advisory Board, which will be chaired by Alex Belser, Cybin’s Chief Clinical Officer. The board will consist of Belser (PhD), Maurizio Fava (MD), Lynn Marie Morski (DM) and Anthony Back (MD). All members of the board have professional experience in either medicine or research. Fava, the Psychiatrist-in-Chief…
-
Predictmedix (PMED.C) engages global investment bank to prep for NASDAQ listing
The Nasdaq Exchange has 3,300 listed stocks including giants such as Apple (AAPL.Q), Google (GOOG.Q), Microsoft (MSFT.Q), Oracle (ORCL.Q), Amazon (AMZN.Q), and Intel (INTC.Q).
-
Parry Special: Short report on Mountain Valley MD Holdings (MVMD.C) earns nothing but rage
When a ‘devastating’ expose on a company opens with the line ‘We are short this company’, I have to say, I find it hard to read much further. To open the discussion admitting you’ll make more money if the company you’re writing about gets obliterated, and then proceed to map out your obliteration strategy, well…
-
Diagnos (ADK.V) uses AI and telemedicine to scan your eye for health issues in 16 countries
In a world where companies toss the term ‘artificial intelligence’ around whenever the office intern figures out how to get a spreadsheet pie chart to update automatically, it’s nice to see a company utilizing actual AI and machine learning in a manner that involves actual intelligence and learning. Diagnos (ADK.V) is a health tech deal…
-
As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat
News this week that Canntab Therapeutics (PILL.C) received an Australian patent for their hard-pressed cannabis pill tech, to match those received earlier in North America, didn’t launch the stock into space. That’s understandable, to be honest, as North American investors have taken an eye off the island continent and its slow roll to weed legalization…
-
Sixth Wave (SIXW.C) surges 15% as Polymer Imprint detects SARS-CoV-2 during initial testing
“Molecularly imprinted polymers (MIPs) are synthetic polymers with a predetermined selectivity for a given analyte, or group of structurally related compounds, making them ideal materials to be used in separation processes,” explains Science Direct.
-
Aequus Pharma (AQS.V) launches Evolve Eyedrops to eye care professionals in Canada
Aequus is a $24 million pharmaceutical company focused on developing and commercializing high quality, differentiated products.
-
Revive Therapeutics (RVV.C) finds $23 million and throws it at their bucillamine clinical studies
Revive Therapeutics (RVV.C) provided an update on their Phase 3 clinical trial for bucillamine for COVID-19 today. Primarily, the update’s about funding and more specifically their recent $23 million financing. The company intends to use the monies to fund their aggressive expansion from14 clinical sites to 50 to meet their enrolment requires for the study…
-
That was quick! Xphyto (XPHY.C) orders 9,600 Covid-19 PCR tests – stock up 67% year-to-date
“PCR tests are used to directly detect the presence of an antigen, rather than the presence of the body’s immune response, or antibodies,” states Medical Device Network, “By detecting viral RNA, which will be present in the body before symptoms of the disease are present,” the tests give a powerful early warning system.